PL3600409T3 - Receptory komórek t i terapia immunologiczna wykorzystująca je przeciwko nowotworom prame-dodatnim - Google Patents
Receptory komórek t i terapia immunologiczna wykorzystująca je przeciwko nowotworom prame-dodatnimInfo
- Publication number
- PL3600409T3 PL3600409T3 PL18715559.3T PL18715559T PL3600409T3 PL 3600409 T3 PL3600409 T3 PL 3600409T3 PL 18715559 T PL18715559 T PL 18715559T PL 3600409 T3 PL3600409 T3 PL 3600409T3
- Authority
- PL
- Poland
- Prior art keywords
- cell receptors
- same against
- immune therapy
- positive cancers
- against prame
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/427—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475329P | 2017-03-23 | 2017-03-23 | |
| DE102017106305.6A DE102017106305A1 (de) | 2017-03-23 | 2017-03-23 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| PCT/EP2018/057482 WO2018172533A2 (en) | 2017-03-23 | 2018-03-23 | T cell receptors and immune therapy using the same against prame positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3600409T3 true PL3600409T3 (pl) | 2024-10-21 |
Family
ID=61899213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18715559.3T PL3600409T3 (pl) | 2017-03-23 | 2018-03-23 | Receptory komórek t i terapia immunologiczna wykorzystująca je przeciwko nowotworom prame-dodatnim |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11236145B2 (pl) |
| EP (2) | EP3600409B1 (pl) |
| JP (2) | JP2020511152A (pl) |
| KR (2) | KR20190132655A (pl) |
| CN (2) | CN110494160B (pl) |
| AU (2) | AU2018240501B2 (pl) |
| BR (1) | BR112019019523A2 (pl) |
| CA (1) | CA3056493A1 (pl) |
| CL (1) | CL2019002645A1 (pl) |
| CO (1) | CO2019011688A2 (pl) |
| CR (1) | CR20190482A (pl) |
| DK (1) | DK3600409T3 (pl) |
| ES (1) | ES2986840T3 (pl) |
| FI (1) | FI3600409T3 (pl) |
| HR (1) | HRP20241228T1 (pl) |
| HU (1) | HUE068640T2 (pl) |
| IL (2) | IL269578B2 (pl) |
| LT (1) | LT3600409T (pl) |
| MA (1) | MA47932B1 (pl) |
| MD (1) | MD3600409T2 (pl) |
| MX (2) | MX2019011260A (pl) |
| MY (1) | MY199084A (pl) |
| PE (1) | PE20191493A1 (pl) |
| PH (1) | PH12019502151A1 (pl) |
| PL (1) | PL3600409T3 (pl) |
| PT (1) | PT3600409T (pl) |
| RS (1) | RS65924B1 (pl) |
| SG (1) | SG11201908023YA (pl) |
| SI (1) | SI3600409T1 (pl) |
| SM (1) | SMT202400351T1 (pl) |
| TW (1) | TWI799922B (pl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| KR20230008254A (ko) | 2017-11-08 | 2023-01-13 | 바이오엔테크 유에스 인크. | T 세포 제조 조성물 및 방법 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| WO2020172332A1 (en) * | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| JP7686571B2 (ja) * | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク，インコーポレーテツド | Ｔ細胞媒介性免疫を調節するための材料及び方法 |
| PE20220164A1 (es) * | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
| BR112022009707A2 (pt) * | 2019-11-18 | 2022-08-09 | BioNTech SE | Receptores de tcr prame e usos dos mesmos |
| AU2021211485A1 (en) * | 2020-01-24 | 2022-09-15 | Regeneron Pharmaceuticals, Inc. | Preferentially expressed antigen in melanoma (PRAME) T cell receptors and methods of use thereof |
| BR112022016909A2 (pt) | 2020-02-24 | 2022-12-06 | Immatics Us Inc | Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022017435A1 (zh) * | 2020-07-22 | 2022-01-27 | 信达生物制药(苏州)有限公司 | 一系列TCR-β链的CDR3序列中共有序列的生物标志物及其应用 |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| AU2022310862A1 (en) | 2021-07-14 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| UY39967A (es) | 2021-10-06 | 2023-05-15 | Immatics Biotechnologies Gmbh | Indicaciones para los aglutinantes anti-PRAME |
| CN113789304B (zh) * | 2021-10-14 | 2023-03-31 | 深圳大学总医院 | 高亲和力tcr及其应用 |
| CN113817044B (zh) * | 2021-10-14 | 2023-10-13 | 深圳大学总医院 | T细胞受体、相关工程化细胞及其应用 |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| AU2023248532A1 (en) | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4514829A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115073584B (zh) * | 2022-05-07 | 2023-10-20 | 溧阳瑅赛生物医药有限公司 | 一种特异性识别prame抗原肽的tcr及其应用 |
| CN116813744B (zh) * | 2023-02-23 | 2024-02-23 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025096983A1 (en) * | 2023-11-02 | 2025-05-08 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| CN107238706A (zh) | 2011-06-28 | 2017-10-10 | 株式会社癌免疫研究所 | 肽癌抗原‑特异性t细胞的受体基因 |
| RU2578009C2 (ru) | 2013-05-08 | 2016-03-20 | Закрытое акционерное общество "ЕВРОГЕН" | Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках |
| MX2017000646A (es) | 2014-07-15 | 2017-04-27 | Juno Therapeutics Inc | Celulas geneticamente modificadas para terapia celular adoptiva. |
| AU2016230828B2 (en) | 2015-03-10 | 2020-10-22 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
| EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| CA2986713A1 (en) | 2015-05-22 | 2016-12-01 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for a prame peptide |
| CN106084036A (zh) | 2015-11-02 | 2016-11-09 | 广州市香雪制药股份有限公司 | 识别prame抗原短肽的t细胞受体 |
| CN106519019B (zh) | 2015-11-06 | 2018-07-03 | 广东香雪精准医疗技术有限公司 | 识别prame抗原的tcr |
| CN106478809B (zh) | 2015-11-06 | 2018-06-01 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的tcr |
| CN106831978B (zh) | 2015-12-04 | 2020-05-26 | 中国科学院广州生物医药与健康研究院 | 识别prame抗原的t细胞受体 |
| CN106699874B (zh) | 2016-03-29 | 2018-06-05 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的t细胞受体 |
| KR102436129B1 (ko) | 2016-06-17 | 2022-08-26 | 메디진 이뮤노테라피스 게엠바하 | T 세포 수용체 및 이의 용도 |
| DE102017106305A1 (de) * | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
-
2018
- 2018-03-22 US US15/928,785 patent/US11236145B2/en active Active
- 2018-03-23 HR HRP20241228TT patent/HRP20241228T1/hr unknown
- 2018-03-23 MX MX2019011260A patent/MX2019011260A/es unknown
- 2018-03-23 JP JP2019552175A patent/JP2020511152A/ja not_active Withdrawn
- 2018-03-23 CN CN201880019206.5A patent/CN110494160B/zh active Active
- 2018-03-23 ES ES18715559T patent/ES2986840T3/es active Active
- 2018-03-23 SI SI201831150T patent/SI3600409T1/sl unknown
- 2018-03-23 SG SG11201908023Y patent/SG11201908023YA/en unknown
- 2018-03-23 MY MYPI2019005257A patent/MY199084A/en unknown
- 2018-03-23 MD MDE20200121T patent/MD3600409T2/ro unknown
- 2018-03-23 EP EP18715559.3A patent/EP3600409B1/en active Active
- 2018-03-23 LT LTEPPCT/EP2018/057482T patent/LT3600409T/lt unknown
- 2018-03-23 KR KR1020197030006A patent/KR20190132655A/ko not_active Ceased
- 2018-03-23 EP EP24194122.8A patent/EP4450087A3/en active Pending
- 2018-03-23 PE PE2019001902A patent/PE20191493A1/es unknown
- 2018-03-23 CR CR20190482A patent/CR20190482A/es unknown
- 2018-03-23 SM SM20240351T patent/SMT202400351T1/it unknown
- 2018-03-23 RS RS20240992A patent/RS65924B1/sr unknown
- 2018-03-23 AU AU2018240501A patent/AU2018240501B2/en active Active
- 2018-03-23 CN CN202410804111.1A patent/CN118852404A/zh active Pending
- 2018-03-23 MA MA47932A patent/MA47932B1/fr unknown
- 2018-03-23 KR KR1020247033132A patent/KR20240151870A/ko active Pending
- 2018-03-23 DK DK18715559.3T patent/DK3600409T3/da active
- 2018-03-23 PT PT187155593T patent/PT3600409T/pt unknown
- 2018-03-23 FI FIEP18715559.3T patent/FI3600409T3/fi active
- 2018-03-23 IL IL269578A patent/IL269578B2/en unknown
- 2018-03-23 CA CA3056493A patent/CA3056493A1/en active Pending
- 2018-03-23 PL PL18715559.3T patent/PL3600409T3/pl unknown
- 2018-03-23 BR BR112019019523-8A patent/BR112019019523A2/pt unknown
- 2018-03-23 HU HUE18715559A patent/HUE068640T2/hu unknown
- 2018-03-23 TW TW110126772A patent/TWI799922B/zh active
-
2019
- 2019-09-16 CL CL2019002645A patent/CL2019002645A1/es unknown
- 2019-09-19 PH PH12019502151A patent/PH12019502151A1/en unknown
- 2019-09-20 MX MX2023003463A patent/MX2023003463A/es unknown
- 2019-10-22 CO CONC2019/0011688A patent/CO2019011688A2/es unknown
-
2021
- 2021-12-16 US US17/553,017 patent/US20220098270A1/en active Pending
-
2023
- 2023-03-20 JP JP2023044130A patent/JP7787119B2/ja active Active
-
2024
- 2024-01-30 IL IL310552A patent/IL310552B1/en unknown
-
2025
- 2025-03-24 AU AU2025202086A patent/AU2025202086A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL310552B1 (en) | T-cell receptors and immunotherapy using them against PRAME-positive cancers | |
| IL271751A (en) | T cell receptors and immunotherapy using them | |
| IL267129A (en) | New T-cell receptors and immunotherapy using them | |
| IL274505A (en) | Transgenic T cell receptors and immunotherapy using them | |
| ZA201900664B (en) | T cell receptors and immune therapy using the same | |
| IL275177A (en) | Enhanced effector training cells and their use | |
| ZA201903333B (en) | Photovoltaic system and associated use | |
| ZA201905054B (en) | Electrosurgical energy conveying structure and electrosurgical device incorporating the same | |
| ZA201707062B (en) | Pod assembly, dispensing body, and e-vapor apparatus including the same | |
| IL267572A (en) | Tumor and immune cell imaging based on pd-l1 expression | |
| SG10202107869QA (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
| ZA202102745B (en) | Anti-ptk7 immune cell cancer therapy | |
| ZA202102740B (en) | Anti-liv1 immune cell cancer therapy | |
| SG11201909751TA (en) | Human alpha fetoprotein-specific t cell receptors and uses thereof | |
| GB2569611B (en) | Improvements in hair-curling devices | |
| GB201709860D0 (en) | Device and charger therefor | |
| ZA201905441B (en) | Antigen receptors and uses thereof | |
| SG11202003404UA (en) | Novel engineered t cell receptors and immune therapy using the same | |
| IL264855B1 (en) | T-cell receptors and immunotherapy using them | |
| IL267131A (en) | Novel t cell receptors and immune therapy using the same | |
| HK40028714A (en) | Novel t cell receptors and immune therapy using the same | |
| HK40010473A (en) | T cell receptors and immune therapy using the same | |
| HK40014642A (en) | Novel t cell receptors and immune therapy using the same |